The Companion Diagnostics (CDX) Market Forecast 2018-2028 - Visiongain Report - Seite 3

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the companion diagnostics market and leading companies. You will find data, trends and predictions. Please order our report now.

To request a report overview of this report please email Sara Peerun at [e-mail] or call Tel: [phone]

Or click on: https://www.visiongain.com/Report/2168/The-Companion-Diagnostics-(CDx)-Market-Forecast-2018-2028

Companies and Organisations Mentioned 

20/20 Gene Systems

Abbott Diagnostics

Abbott Molecular

Affymetrix

Agilent (Dako)

Almac

Ambry Genetics

Amgen

Arca bipharma

Arno

Astellas Pharma

AstraZeneca

Asuragen

Bayer

Biogenex Laboratories, Inc.

bioMérieux

Biomonitor

Boehringer Ingelheim

Brain Resource Company

Bristol-Myers Squibb

Cancer Research UK

CancerGuide Diagnostics

Caprion Proteomics

Caris Life Sciences

Celera (acquired by Quest Diagnostics)

Celgene

Cepheid

ChemGenex Pharmaceuticals

Clarient

Clinical Reference Laboratory

Clovis

College of American Pathology (CAP)

CompanDx

Crescendo Bioscience

Curidium Medica

Dako (Agilent)

Deloitte

DiagnoCure

Dx assays

DxS

Eli Lilly

Endocyte

European Medicines Agency (EMA)

Exosome Diagnostics

Ferring

Flagship Biosciences

FlowMetric Diagnostics

Foundation Medical

Foundation Medicine

Genentech

Genfit

Genia Technologies

Genmab

GenMark Diagnostics

Gilead Sciences

GlaxoSmithKline

GSK

Hexie Health

HistologiX

Idera

Illumina

ImmunoGen

Incyte

InDex Pharmaceuticals

IntegraGen

Inverness Medical Innovations (now known as Alere)

Invivoscribe Technologies

Ipsen

Ipsogen

IQuum